We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Dicerna's (DRNA) A1AT Candidate Gets Orphan Drug Tag in EU
Read MoreHide Full Article
Dicerna Pharmaceuticals, Inc. announced that the European Commission (EC) has granted orphan drug designation to its RNAi therapeutic DCR-A1AT, currently being developed for treating congenital alpha-1 antitrypsin (A1AT) deficiency, a protein primarily produced in and released from the liver.
The prestigious tag for DCR-A1AT was based on a positive opinion from the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP). Currently, there are no approved therapies to treat A1AT deficiency-associated liver disease.
The EMA usually grants orphan medicinal product status to drugs that target serious or life-threatening conditions, which are being developed to treat, prevent or diagnose diseases or conditions affecting not more than five in 10,000 people in the region. In addition to providing Dicerna with certain benefits and incentives, this status will allow DCR-A1AT to enjoy a period of market exclusivity in the EU, if approved, for the treatment of A1AT deficiency.
Dicerna submitted a clinical trial application to the Swedish Medical Products Agency for DCR-A1AT to treat patients with A1AT deficiency-associated liver disease in June 2019. The company began enrolling healthy volunteers during the fourth quarter in the phase I/II study on DCR-A1AT.
Notably, DCR-A1AT is being evaluated in a phase I/II study for the treatment of liver disease in patients with alpha-1 antitrypsin (A1AT) deficiency.
Shares of Dicerna have skyrocketed 146.5% so far this year, significantly outperforming the industry’s increase of 8.6%.
Apart from DCR-A1AT, Dicerna’s other priority programs are DCR-PHXC, which is being developed for the treatment of primary hyperoxaluria, and DCR-HBVS, presently being evaluated to address chronic hepatitis B virus (HBV) infection.
We remind investors that Dicerna has strategic alliances with several pharma and biotech companies, such as Roche (RHHBY - Free Report) , Eli Lilly (LLY - Free Report) , Alexion Pharmaceuticals and Boehringer Ingelheim International GmbH.
Earlier this week, Alexion exercised its option for gaining exclusive rights to two additional GalXC RNAi targets within the complement pathway, taking the number of targets to four in the existing collaboration agreement. Per the deal, Dicerna is eligible to receive a total of $20 million from Alexion.
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.6% per year. So be sure to give these hand-picked 7 your immediate attention.
Image: Bigstock
Dicerna's (DRNA) A1AT Candidate Gets Orphan Drug Tag in EU
Dicerna Pharmaceuticals, Inc. announced that the European Commission (EC) has granted orphan drug designation to its RNAi therapeutic DCR-A1AT, currently being developed for treating congenital alpha-1 antitrypsin (A1AT) deficiency, a protein primarily produced in and released from the liver.
The prestigious tag for DCR-A1AT was based on a positive opinion from the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP). Currently, there are no approved therapies to treat A1AT deficiency-associated liver disease.
The EMA usually grants orphan medicinal product status to drugs that target serious or life-threatening conditions, which are being developed to treat, prevent or diagnose diseases or conditions affecting not more than five in 10,000 people in the region. In addition to providing Dicerna with certain benefits and incentives, this status will allow DCR-A1AT to enjoy a period of market exclusivity in the EU, if approved, for the treatment of A1AT deficiency.
Dicerna submitted a clinical trial application to the Swedish Medical Products Agency for DCR-A1AT to treat patients with A1AT deficiency-associated liver disease in June 2019. The company began enrolling healthy volunteers during the fourth quarter in the phase I/II study on DCR-A1AT.
Notably, DCR-A1AT is being evaluated in a phase I/II study for the treatment of liver disease in patients with alpha-1 antitrypsin (A1AT) deficiency.
Shares of Dicerna have skyrocketed 146.5% so far this year, significantly outperforming the industry’s increase of 8.6%.
Apart from DCR-A1AT, Dicerna’s other priority programs are DCR-PHXC, which is being developed for the treatment of primary hyperoxaluria, and DCR-HBVS, presently being evaluated to address chronic hepatitis B virus (HBV) infection.
We remind investors that Dicerna has strategic alliances with several pharma and biotech companies, such as Roche (RHHBY - Free Report) , Eli Lilly (LLY - Free Report) , Alexion Pharmaceuticals and Boehringer Ingelheim International GmbH.
Earlier this week, Alexion exercised its option for gaining exclusive rights to two additional GalXC RNAi targets within the complement pathway, taking the number of targets to four in the existing collaboration agreement. Per the deal, Dicerna is eligible to receive a total of $20 million from Alexion.
Zacks Rank
Dicerna currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.6% per year. So be sure to give these hand-picked 7 your immediate attention.
See 7 handpicked stocks now >>